CN116444425A - 微管蛋白-src双靶点抑制剂 - Google Patents
微管蛋白-src双靶点抑制剂 Download PDFInfo
- Publication number
- CN116444425A CN116444425A CN202310074547.5A CN202310074547A CN116444425A CN 116444425 A CN116444425 A CN 116444425A CN 202310074547 A CN202310074547 A CN 202310074547A CN 116444425 A CN116444425 A CN 116444425A
- Authority
- CN
- China
- Prior art keywords
- ring
- pharmaceutically acceptable
- alkyl
- halogen
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 title abstract description 20
- 230000009977 dual effect Effects 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 93
- 150000003839 salts Chemical class 0.000 claims abstract description 41
- 102000009076 src-Family Kinases Human genes 0.000 claims abstract description 22
- 108010087686 src-Family Kinases Proteins 0.000 claims abstract description 22
- 229940043355 kinase inhibitor Drugs 0.000 claims abstract description 7
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims abstract description 7
- -1 hydroxy, amino Chemical group 0.000 claims description 46
- 229910052736 halogen Inorganic materials 0.000 claims description 43
- 150000002367 halogens Chemical class 0.000 claims description 43
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 41
- 125000001424 substituent group Chemical group 0.000 claims description 38
- 125000000623 heterocyclic group Chemical group 0.000 claims description 35
- 238000002360 preparation method Methods 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
- 229920006395 saturated elastomer Polymers 0.000 claims description 14
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 claims description 13
- 102000004243 Tubulin Human genes 0.000 claims description 13
- 108090000704 Tubulin Proteins 0.000 claims description 13
- 230000005764 inhibitory process Effects 0.000 claims description 13
- 125000002947 alkylene group Chemical group 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 125000005842 heteroatom Chemical group 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 239000011737 fluorine Substances 0.000 claims description 8
- 208000017520 skin disease Diseases 0.000 claims description 8
- 125000003003 spiro group Chemical group 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 208000009621 actinic keratosis Diseases 0.000 claims description 5
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 2
- 208000021309 Germ cell tumor Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 230000002489 hematologic effect Effects 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000008585 mastocytosis Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 238000006116 polymerization reaction Methods 0.000 abstract description 9
- 239000000178 monomer Substances 0.000 abstract description 6
- 230000004663 cell proliferation Effects 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 48
- 125000004432 carbon atom Chemical group C* 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 239000012074 organic phase Substances 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 229930195733 hydrocarbon Natural products 0.000 description 9
- 102000029749 Microtubule Human genes 0.000 description 8
- 108091022875 Microtubule Proteins 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 125000001183 hydrocarbyl group Chemical group 0.000 description 8
- 210000004688 microtubule Anatomy 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 7
- 125000002950 monocyclic group Chemical group 0.000 description 7
- 239000003208 petroleum Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 6
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- MFVMVBWFPPMPFW-UHFFFAOYSA-N n-benzyl-2-(5-bromopyridin-2-yl)acetamide Chemical compound N1=CC(Br)=CC=C1CC(=O)NCC1=CC=CC=C1 MFVMVBWFPPMPFW-UHFFFAOYSA-N 0.000 description 4
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 4
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- ROKZLWJDYXOQSZ-UHFFFAOYSA-N 4-(4-bromophenoxy)-2-methylbutan-2-ol Chemical compound CC(C)(O)CCOC1=CC=C(Br)C=C1 ROKZLWJDYXOQSZ-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 description 2
- 125000005999 2-bromoethyl group Chemical group 0.000 description 2
- RBFVGQWGOARJRU-UHFFFAOYSA-N 4-bromo-2-methylbutan-2-ol Chemical compound CC(C)(O)CCBr RBFVGQWGOARJRU-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000037845 Cutaneous squamous cell carcinoma Diseases 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 229940122530 Tubulin polymerization inhibitor Drugs 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 2
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 238000004262 preparative liquid chromatography Methods 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- HUNGUWOZPQBXGX-UHFFFAOYSA-N tirbanibulin Chemical compound C=1C=CC=CC=1CNC(=O)CC(N=C1)=CC=C1C(C=C1)=CC=C1OCCN1CCOCC1 HUNGUWOZPQBXGX-UHFFFAOYSA-N 0.000 description 2
- 229940121511 tirbanibulin Drugs 0.000 description 2
- JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium ethoxide Chemical compound [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- DQXKOHDUMJLXKH-PHEQNACWSA-N (e)-n-[2-[2-[[(e)-oct-2-enoyl]amino]ethyldisulfanyl]ethyl]oct-2-enamide Chemical compound CCCCC\C=C\C(=O)NCCSSCCNC(=O)\C=C\CCCCC DQXKOHDUMJLXKH-PHEQNACWSA-N 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- BROSMYXVSSCLGP-UHFFFAOYSA-N 1-(2-bromoethyl)cyclopropan-1-ol Chemical compound BrCCC1(O)CC1 BROSMYXVSSCLGP-UHFFFAOYSA-N 0.000 description 1
- SRGBSEMMGLSUMI-UHFFFAOYSA-N 1-bromo-4-(2-bromoethoxy)benzene Chemical compound BrCCOC1=CC=C(Br)C=C1 SRGBSEMMGLSUMI-UHFFFAOYSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- JNOZGFXJZQXOSU-UHFFFAOYSA-N 1-chloro-2-methylpropan-2-ol Chemical compound CC(C)(O)CCl JNOZGFXJZQXOSU-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- BMIBJCFFZPYJHF-UHFFFAOYSA-N 2-methoxy-5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC=C(C)C=C1B1OC(C)(C)C(C)(C)O1 BMIBJCFFZPYJHF-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- FQEYHIPPYOSPLF-UHFFFAOYSA-N 4-bromo-3-chlorophenol Chemical compound OC1=CC=C(Br)C(Cl)=C1 FQEYHIPPYOSPLF-UHFFFAOYSA-N 0.000 description 1
- GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical compound OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 1
- CXBLQEIODBBSQD-UHFFFAOYSA-N 4-methylpiperidin-4-ol Chemical compound CC1(O)CCNCC1 CXBLQEIODBBSQD-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229920002430 Fibre-reinforced plastic Polymers 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000004452 carbocyclyl group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- FQTIYMRSUOADDK-UHFFFAOYSA-N ethyl 3-bromopropanoate Chemical compound CCOC(=O)CCBr FQTIYMRSUOADDK-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000011151 fibre-reinforced plastic Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000006343 heptafluoro propyl group Chemical group 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 230000008880 microtubule cytoskeleton organization Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108090000446 ribonuclease T(2) Proteins 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 230000020347 spindle assembly Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/57—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
本发明公开了一种微管蛋白‑SRC双靶点抑制剂。本发明提供了一种如式I所示化合物或其药学上可接受的盐;其可以作为微管蛋白和Src激酶双靶点抑制剂,也可以作为单独的微管蛋白或Src激酶抑制剂使用,能明显抑制微管蛋白单体的聚合和抑制细胞增殖。
Description
技术领域
本发明属于医药领域,具体地,本发明涉及到一种微管蛋白-SRC双靶点抑制剂。
背景技术
微管是真核细胞中细胞骨架的重要组成部分,在维持细胞形态、信号传递、细胞器运输、细胞运动、细胞分裂和有丝分裂等多种细胞功能中发挥着重要作用(Jordan M A etal.Nature Reviews Cancer,2004,4(4):253-265.)。
微管由两种类型的微管蛋白亚基,即α-微管蛋白和β-微管蛋白组成,α-微管蛋白和β-微管蛋白形成微管蛋白异二聚体,是微管装配的基本单位。微管靶向剂(Microtubule-targeting agents,MTAs)能破坏微管的动力学稳定性和结构,干扰有丝分裂纺锤体的形成,诱导细胞周期阻滞于G2/M期,促使细胞凋亡(Shuai W et al.Journal of MedicinalChemistry,2021,64(12).)。
微管参与很多重要的细胞过程,已成为治疗过度增殖性疾病最重要的药物靶点之一,美国FDA批准的几种微管靶向剂如长春花碱和紫杉烷类化合物被广泛用于治疗多实体肿瘤和血液系统恶性肿瘤,但微管靶向药物的耐药性和剂量限制性毒性限制了其临床疗效。双靶点抑制剂与单靶点药物相比克服了耐药性,可以改善治疗效果,已成为研究热点,如:微管蛋白-SRC双靶点抑制剂、微管蛋白-受体酪氨酸激酶(receptor tyrosine Binasesinhibitor,RTB)双靶点抑制剂、微管蛋白-组蛋白去乙酰化酶(histone deacetylasesinhibitor,HDAC)双靶点抑制剂等(Shuai W et al.Journal ofMedicinal Chemistry,2021,64(12).)。
光化性角化病(Actinic Beratosis,AB)是一种与长时间暴露在紫外线下有关的皮肤病,在美国AB是皮肤科医生第二常见的疾病,特征是突变的角质形成细胞不受控制的增殖,其被认为是一种癌前病变,如果不及时治疗,20%的病例可能会发展为皮肤鳞状细胞癌(SCC)。目前微管蛋白-SRC双靶点抑制剂TiRbanibulin临床上局部治疗AB效果显著(NCT03285477),已被FDA批准上市,这表明开发新的具有更好效果的微管蛋白-SRC双靶点抑制剂局部治疗AB可能是一个有潜力的方向。
发明内容
本发明的目的是提供一种微管蛋白-SRC双靶点抑制剂,所述双靶点抑制剂具有如本发明中式I所述的结构,其可以作为微管蛋白和Src激酶双靶点抑制剂,也可以作为单独的微管蛋白或Src激酶抑制剂使用。
在本发明第一方面,提供了一种式I所示化合物或其药学上可接受的盐,具有结构:
其中,W选自:-O-、-S-、-NH-、-N(C1-C6烷基)-;
Q为
L1为C1-C6亚烷基;
L2、L3各自独立地为不存在或为C1-C6亚烷基;
且L2和L3不同时不存在;
环A为3-6元环烷基或4-8元杂环基;
环B不存在或选自:3-8元环烷基、4-10元杂环基、6-10元芳基、5-10元杂芳基;
所述L1、L2、L3任选地被一个或多个RL取代;当RL为多个时,所述RL相同或不同;
RL、Rb、R1、R2各自独立地选自:卤素、羟基、氨基、氰基、C1-C6烷基、C2-C6烯基、C2-C6炔基、-O-C1-C6烷基、-COO-C1-C6烷基、-CO-C1-C6烷基、-C(O)NR11R12;
其中,R11、R12各自独立地为氢、C1-C6烷基;
所述RL、Rb、R1、R2任选地被一个或多个选自下列的取代基取代:卤素、羟基、氨基、氰基、C1-C6烷基,当取代基为多个时,所述取代基相同或不同;
m为0、1、2或3;当Rb为多个时,所述Rb相同或不同;
n为0、1、2或3;当R1为多个时,所述R1相同或不同;
p为0、1、2或3;当R2为多个时,所述R2相同或不同。
本发明中,所述的式I所示化合物或其药学上可接受的盐中某些取代基的定义可如下所述,未提及的取代基的定义均如本申请中任一方案所述(以下简称“在一优选实施例中”、“在一优选实施方式中”或“在一优选实施方案中”):
在一优选实施例中,W选自-O-;
Q为
L1为C1-C6亚烷基;
环B不存在或选自:3-8元环烷基、4-10元杂环基;
Rb、R1各自独立地选自:卤素、C1-C6烷基;
m为0或1;
n为0或1;
p为0。
在一优选实施例中,L1优选C1-C3亚烷基或进一步优选-CH2-、-CH2CH2-、-CH2CH2CH2-或/>其左端与羟基或环B相连。
在一优选实施例中,所述的环B里,所述的3-8元环烷基为3-6元环烷基。
在一优选实施例中,所述的环B里,所述的3-8元环烷基为单环、并环、桥环或螺环。
在一优选实施例中,所述的环B里,所述的3-8元环烷基为饱和环。
在一优选实施例中,所述的环B里,所述的3-8元环烷基为环丙基。
在一优选实施例中,所述的环B里,所述的3-8元环烷基为环丙基、环丁基、环戊基、环己基。
在一优选实施例中,所述的环B里,所述的4-10元杂环基为4-6元杂环基。
在一优选实施例中,所述的环B里,所述的4-10元杂环基为单环、并环、桥环或螺环。
在一优选实施例中,所述的环B里,所述的4-10元杂环基为饱和环。
在一优选实施例中,为/>
在一优选实施例中,所述的环B里,所述的4-10元杂环基中的杂原子为N。
在一优选实施例中,所述的环B里,所述的4-10元杂环基中的杂原子为N或O。
在一优选实施例中,所述的环B里,所述的4-10元杂环基通过N原子与L1连接。
在一优选实施例中,所述环B里,所述的4-10元杂环基为
在一优选实施例中,所述的Rb里,所述的卤素为氟或氯。
在一优选实施例中,所述的Rb里,所述的C1-C6烷基为甲基或乙基。
在一优选实施例中,所述的R1里,所述的卤素为氟或氯。
在一优选实施例中,所述的R1里,所述的C1-C6烷基为甲基或乙基。
在一优选实施例中,选自:/>
在一优选实施例中,选自:/>
在一优选实施例中,W选自:-O-、-S-、-NH-;较佳地,W为-O-。
在一优选实施例中,为/>
在一优选实施例中,L1为C1-C3亚烷基;L2、L3各自独立地为不存在或为C1-C3亚烷基;且L2和L3不同时不存在。
在一优选实施例中,环A为3-6元环烷基或4-6元杂环基;L1、L2、L3任选地被一个或多个RL取代;当RL为多个时,所述RL相同或不同;
所述RL选自:卤素、羟基、氨基、氰基、C1-C6烷基、-O-C1-C6烷基;所述RL任选地被一个或多个选自下列的取代基取代:卤素、羟基、氨基、氰基、C1-C6烷基;当取代基为多个时,所述取代基相同或不同;
较佳地,所述RL选自:C1-C6烷基或C1-C6卤代烷基;较佳地,环A为3-6元环烷基;较佳地,环A为环丙基、环丁基、环戊基、环己基;较佳地,所述卤素为F。
在一优选实施例中,环B选自:3-8元环烷基、4-10元杂环基;较佳地,环B选自:3-6元环烷基、4-6元杂环基;较佳地,所述环B为单环、并环、桥环、螺环;较佳地,所述3-6元环烷基、4-6元杂环基为单环;较佳地,所述环B具有1、2或3选自N、O、S、P的杂原子;较佳地,所述环B具有S杂原子,所述环B具有结构
在一优选实施例中,m为0、1或2;Rb选自:卤素、羟基、氨基、氰基、C1-C3烷基、C2-C4烯基、C2-C4炔基、-O-C1-C3烷基、-COO-C1-C3烷基、-CO-C1-C3烷基、-C(O)NR11R12;
其中,R11、R12各自独立地为氢、甲基、乙基、丙基;
所述Rb任选地被一个或多个选自下列的取代基取代:卤素、羟基、氨基、氰基、C1-C3烷基,当取代基为多个时,所述取代基相同或不同;或Rb选自:卤素、羟基、氨基、氰基、C1-C6烷基、-O-C1-C6烷基;
所述Rb任选地被一个或多个选自下列的取代基取代:卤素、C1-C6烷基;当取代基为多个时,所述取代基相同或不同;
较佳地,Rb选自:C1-C6烷基;所述Rb任选地被一个或多个卤素取代;当卤素为多个时,所述卤素相同或不同;较佳地,Rb选自:甲基、乙基、丙基、异丙基;所述Rb任选地被一个或多个卤素取代;当卤素为多个时,所述卤素相同或不同;较佳地,所述卤素为F。
在一优选实施例中,具有结构
在一优选实施例中,n为0或1;R1选自:卤素、氰基、C1-C6烷基;
较佳地,R1选自:氟、氰基、甲基。
较佳地,R1选自:氟、氯、氰基、甲基。
在一优选实施例中,p为0。
在一优选实施例中,所述式I所示化合物或其药学上可接受的盐里,所述式I所示化合物为如下任一化合物:
一种化合物,其为如下任一结构
在本发明第二方面,提供了一种药物组合物,包括如第一方面任一所述的化合物或其药学上可接受的盐。
提供了一种药物组合物,包括如第一方面任一所述的化合物或其药学上可接受的盐,和药学上可接受的载体和/或其他活性药物。
在本发明第三方面,提供了如第一方面任一所述的化合物或其药学上可接受的盐的用途,或第二方面任一所述的药物组合物的用途,所述用途包括:
1)抑制微管蛋白聚合和/或Src激酶;
2)制备微管蛋白聚合和/或Src激酶抑制剂;
3)制备预防和/或治疗与微管蛋白聚合和/或Src激酶相关的疾病的药物、药物组合物或制剂。
较佳地,所述用途包括:抑制微管蛋白聚合;和/或,预防和/或治疗微管蛋白聚合相关的疾病;和/或,制备微管蛋白聚合抑制剂,和/或,制备预防和/或治疗与微管蛋白聚合相关的疾病的药物、药物组合物或制剂。
较佳地,所述用途包括:抑制Src激酶;和/或,预防和/或治疗Src激酶相关的疾病;和/或,制备Src激酶抑制剂;和/或,制备预防和/或治疗与Src激酶相关的疾病的药物、药物组合物或制剂。
较佳地,所述药物为外用制剂。
较佳地,所述药物为经皮给药的药物。
较佳地,所述微管蛋白聚合和/或Src激酶相关的疾病包括肿瘤、皮肤疾病。
本发明第四方面,提供了如第一方面中任一所述的化合物或其药学上可接受的盐在制备治疗肿瘤和/或皮肤疾病的药物中的用途;或如第二方面任一所述的药物组合物在制备治疗肿瘤和/或皮肤疾病的药物中的用途。
较佳地,所述药物为外用制剂。
较佳地,所述药物为经皮给药的药物。
在一优选实施例中,所述肿瘤包括:实体瘤、肉瘤、血液系统癌症;
较佳地,所述肿瘤包括:乳腺癌、卵巢癌、前列腺癌、子宫颈癌、睾丸癌、结肠癌、结肠直肠癌、肝癌、非小细胞肺癌、鳞状细胞癌(例如皮肤鳞状细胞癌)、小细胞肺癌、胃癌、胃肠道间质瘤、胰腺癌、膀胱癌、生殖细胞瘤、肥大细胞瘤、肥大细胞增多症、胶质母细胞瘤、神经母细胞瘤、星形细胞瘤、黑色素瘤、B细胞淋巴瘤、T细胞淋巴瘤、缓慢进展淋巴瘤、霍奇金淋巴瘤、非霍奇金淋巴瘤、急性髓细胞性白血病、急性淋巴细胞性白血病、慢性髓细胞性白血病、慢性淋巴细胞性白血病、骨髓瘤和/或骨髓增生异常综合症。
在一优选实施例中,所述皮肤疾病包括:光化性角化病、银屑病、异位性皮炎、牛皮癣、白癜风、玫瑰疹和/或系统性红斑狼疮。
在本发明第五方面,提供了一种抑制Src激酶的方法,包括步骤:给需要的对象使用如本发明第一方面所述的化合物或其药学上可接受的盐,或如本发明第二方面所述的药物组合物。
在本发明第六方面,提供了一种抑制微管蛋白的方法,包括步骤:给需要的对象使用如本发明第一方面所述的化合物或其药学上可接受的盐,或如本发明第二方面所述的药物组合物。
本发明的附加方面和优点将在下面的描述中部分给出,部分将从下面的描述中变得明显,或通过本发明的实践了解到。
术语和定义
除非另有说明,本申请说明书和权利要求书中记载的基团和术语定义,包括其作为实例的定义、示例性的定义、优选的定义、表格中记载的定义、实施例中具体化合物的定义等,可以彼此之间任意组合和结合。这样的组合和结合后的基团定义及化合物结构,应当属于本申请说明书记载的范围内。
除非另有定义,否则本文所有科技术语具有的涵义与权利要求主题所属领域技术人员通常理解的涵义相同。除非另有说明,本文全文引用的所有专利、专利申请、公开材料通过引用方式整体并入本文。如果本文对术语有多个定义,以本章的定义为准。
应理解,上述简述和下文的详述为示例性且仅用于解释,而不对本发明主题作任何限制。在本申请中,除非另有具体说明,否则使用单数时也包括复数。必须注意,除非文中另有清楚的说明,否则在本说明书和权利要求书中所用的单数形式包括所指事物的复数形式。还应注意,除非另有说明,否则所用“或”、“或者”表示“和/或”。此外,所用术语“包括”以及其它形式,例如“包含”、“含”和“含有”并非限制性。
可在参考文献(包括Carey and Sundberg″ADVANCED ORGANIC CHEMISTRY4THED.″Vols.A(2000)and B(2001),Plenum Press,New YoRb)中找到对标准化学术语的定义。除非另有说明,否则采用本领域技术范围内的常规方法,如质谱、NMR、IR和UV/VIS光谱法和药理学方法。除非提出具体定义,否则本文在分析化学、有机合成化学以及药物和药物化学的有关描述中采用的术语是本领域已知的。可在化学合成、化学分析、药物制备、制剂和递送,以及对患者的治疗中使用标准技术。例如,可利用厂商对试剂盒的使用说明,或者按照本领域公知的方式或本发明的说明来实施反应和进行纯化。通常可根据本说明书中引用和讨论的多个概要性和较具体的文献中的描述,按照本领域熟知的常规方法实施上述技术和方法。在本说明书中,可由本领域技术人员选择基团及其取代基以提供稳定的结构部分和化合物。
当通过从左向右书写的常规化学式描述取代基时,该取代基也同样包括从右向左书写结构式时所得到的在化学上等同的取代基。举例而言,CH2O等同于OCH2。如本文所用,表示基团的连接位点。
本文所用的章节标题仅用于组织文章的目的,而不应被解释为对所述主题的限制。本申请中引用的所有文献或文献部分包括但不限于专利、专利申请、文章、书籍、操作手册和论文,均通过引用方式整体并入本文。
除前述以外,当用于本申请的说明书及权利要求书中时,除非另外特别指明,否则以下术语具有如下所示的含义。
本申请说明书和权利要求书记载的数值范围,当该数值范围被理解为“整数”时,应当理解为记载了该范围的两个端点以及该范围内的每一个整数。例如,“1~6的整数”应当理解为记载了0、1、2、3、4、5和6的每一个整数。
在本申请中,在单独或作为其他取代基一部分时,术语“卤素”是指氟、氯、溴、碘。
如本文所用,在单独或作为其他取代基一部分时,术语“烷基”意指仅由碳原子和氢原子组成、不含不饱和键、具有例如1至6个碳原子且通过单键与分子的其余部分连接的直链或支链的烃链基团。烷基的实例包括但不限于甲基、乙基、正丙基、异丙基、正丁基、异丁基,叔丁基,戊基,异戊基,新戊基和己基。烷基也可以是富含碳和/或氢的同位素(即氘或氚)的天然丰度烷基的同位素异构体。如本文所用,术语“烯基”表示无支链或支链的单价烃链,其含有一个或多个碳-碳双键。如本文所用,术语“炔基”是指无支链或支链的一价烃链,其含有一个或多个碳-碳三键。
在单独或作为其他取代基一部分时,术语“C1-C6烷基”应理解为表示具有1、2、3、4、5或6个碳原子的直链或支链饱和一价烃基。所述烷基是例如甲基、乙基、丙基、丁基、戊基、己基、异丙基、异丁基、仲丁基、叔丁基、异戊基、2-甲基丁基、1-甲基丁基、1-乙基丙基、1,2-二甲基丙基、新戊基、1,1-二甲基丙基、4-甲基戊基、3-甲基戊基、2-甲基戊基、1-甲基戊基、2-乙基丁基、1-乙基丁基、3,3-二甲基丁基、2,2-二甲基丁基、1,1-二甲基丁基、2,3-二甲基丁基、1,3-二甲基丁基或1,2-二甲基丁基等或它们的异构体。特别地,所述基团具有1、2或3个碳原子(“C1-C3烷基”),例如甲基、乙基、正丙基或异丙基。
在单独或作为其他取代基一部分时,术语“亚烷基”表示从饱和的直链或支链烃基中去掉两个氢原子所得到的饱和的二价烃基基团。亚烷基基团的实例包括亚甲基(-CH2-),亚乙基(包括-CH2CH2-或-CH(CH3)-),亚异丙基(包括-CH(CH3)CH2-或-C(CH3)2-)等等。
在单独或作为其他取代基一部分时,术语“碳环”、“烯环”、“环烷基”或“碳环基”是指一种环状烷基。术语“m-n元环烷基”或者“Cm-Cn环烷基”具有相同的定义,应理解为表示具有m至n个原子的饱和、不饱和或部分饱和的碳环。例如,“3-8元环烷基”则含有3-8个碳原子。包括单环、二环、三环、螺环或桥环。未取代的环烷基的实例包括但不限于环丙基,环丁基,环戊基,环己基和金刚烷基,或者是双环烃基如十氢化萘环。环烷基可以被一个或多个取代基取代。术语“3-6元环烷基”应理解为表示饱和的一价单环或双环烃环,其具有3~6个碳原子,包括稠合或桥接的多环系统。例如环丙基、环丁基、环戊基、环己基。未取代的环烷基的实例包括但不限于环丙烯基,环丁烯基,环戊烯基,环己烯基和环己二烯基。在一些实施方案中,3-15元环烷基优选3-10元环烷基;更优选3-8元环烷基。
在单独或作为其他取代基一部分时,“卤代烷基”指包括具有特定数目的碳原子、被一或多个卤素取代的支链和直链的饱和脂族烃基(如-CvFw,其中v=1至3,w=1至(2v+1))。卤代烷基的实例包括,但不限于三氟甲基、三氯甲基、五氟乙基、五氯乙基、2,2,2-三氟乙基、七氟丙基和七氯丙基。
术语“C2-C6烯基”应理解为表示直连或支链的一价烃基,其包含一个或多个双键并且具有2、3、4、5或6个碳原子,具有2或3个碳原子(即,C2-C3烯基)。应理解,在所述烯基包含多于一个双键的情况下,所述双键可相互分离或者共轭。所述烯基是例如乙烯基、烯丙基、(E)-2-甲基乙烯基、(Z)-2-甲基乙烯基、(E)-丁-2-烯基、(Z)-丁-2-烯基、(E)-丁-1-烯基、(Z)-丁-1-烯基。
术语“C2-C6炔基”应理解为表示直连或支链的一价烃基,其包含一个或多个三键并且具有2、3、4、5或6个碳原子,具有2或3个碳原子(“C2-C3炔基”)。所述炔基是例如乙炔基、丙-1-炔基、丙-2-炔基、丁-1-炔基、丁-2-炔基、丁-3-炔基。
术语“6-10元芳基”应理解为具有6~10个碳原子的一价芳香性或部分芳香性的单环、双环或三环烃环,特别是具有6个碳原子的环(“C6芳基”),例如苯基;或联苯基,或者是具有9个碳原子的环(“C9芳基”),例如茚满基或茚基,或者是具有10个碳原子的环(“C10芳基”),例如四氢化萘基、二氢萘基或萘基。当所述C6-C10芳基被取代时,其可以为单取代或者多取代。并且,对其取代位点没有限制,例如可以为邻位、对位或间位取代。
术语“5-10元杂芳基”应理解为具有5~10个环原子且包含1-5个独立选自N、O和S的杂原子的一价单环、双环或三环芳族环基团,例如“5-14元杂芳基”。术语“5-14元杂芳基”应理解为具有5、6、7、8、9、10、11、12、13或14个环原子——特别是5或6或9或10个碳原子——且其包含1-5个,优选1-3个——独立选自N、O和S的杂原子的一价单环、双环或三环芳族环基团,并且,另外在每一种情况下可为苯并稠合的。特别地,杂芳基选自噻吩基、呋喃基、吡咯基、噁唑基、噻唑基、咪唑基、吡唑基、异噁唑基、异噻唑基、噁二唑基、三唑基、噻二唑基等以及它们的苯并衍生物,例如苯并呋喃基、苯并噻吩基、苯并噁唑基、苯并异噁唑基、苯并咪唑基、苯并三唑基、吲唑基、吲哚基、异吲哚基等;或吡啶基、哒嗪基、嘧啶基、吡嗪基、三嗪基等,以及它们的苯并衍生物,例如喹啉基、喹唑啉基、异喹啉基等;或吲嗪基、嘌呤基等以及它们的苯并衍生物;或酞嗪基、喹唑啉基、喹喔啉基等。
在单独或作为其他取代基一部分时,术语“杂环”、“杂环烷基”或“杂环基”具有相同的定义。术语“4-10元杂环基”或者应理解为表示具有4至10个原子的饱和、不饱和或部分饱和的单环、二环或三环,其中1、2、3、4或5个环原子选自N、O、S和P(优选地选自N、O、S);应该理解的是,当杂环基中S原子和O原子的总数超过1时,这些杂原子不彼此相邻。若所述杂环基为单环,则其一定不是芳族的。杂环基的实例包括但不限于哌啶基、哌嗪基、氮杂环丁烷基、氧杂环丁烷基、吗啉基、四氢异喹啉基、四氢喹啉基、二氢吲哚基、四氢吡喃基、二氢-2H-吡喃基、四氢呋喃基、四氢噻喃基。术语“4-6元杂环基”应理解为具有4-6个原子的饱和、不饱和或部分饱和的单环,其中1、2、3或4个(较佳地为1、2或3个)环原子选自N、O和S。
术语“并环”是指化合物中的任意两个环共用两直接相连的碳原子的环烃,根据组成环的数目分为二环烃、三环烃、四环烃等。非限制性实例包括:
术语“螺环”指单环之间共用一个碳原子(称螺原子)的多环基团,其可以含有一个或多个双键,但没有一个环具有完全共轭的π电子系统。优选为6至12元,更优选为7至8元。根据环与环之间共用螺原子的数目将螺环烷基分为单螺环烷基、双螺环烷基或多螺环烷基,优选为单螺环烷基和双螺环烷基。更优选为4元/4元、4元/5元、4元/6元、5元/5元或5元/6元单螺环烷基。螺环烷基的非限制性实例包括:
也包含单螺环烷基与杂环烷基共用螺原子的螺环烷基,非限制性实例包括:
术语“桥环”是指化合物中的任意两个环共用两不直接相连的碳原子的环烃,根据组成环的数目分为二环烃、三环烃、四环烃等。非限制性实例包括:
在本申请中,“任选的”或“任选地”表示随后描述的事件或状况可能发生也可能不发生,且该描述同时包括该事件或状况发生和不发生的情况。例如,“任选地被取代的芳基”表示芳基被取代或未被取代,且该描述同时包括被取代的芳基与未被取代的芳基。
在本申请中,术语“盐”或“药学上可接受的盐”,包括药学上可接受的酸加成盐和药学上可接受的碱加成盐。术语“药学上可接受的”,是针对那些化合物、材料、组合物和/或剂型而言,它们在可靠的医学判断的范围之内,适用于与人类和动物的组织接触使用,而没有过多的毒性、刺激性、过敏性反应或其它问题或并发症,与合理的利益/风险比相称。
“药学上可接受的酸加成盐”是指能够保留游离碱的生物有效性而无其它副作用的,与无机酸或有机酸所形成的盐。“药学上可接受的碱加成盐”是指能够保持游离酸的生物有效性而无其它副作用的、与无机碱或有机碱所形成的盐。除了药学可接受的盐外,本发明还考虑其他盐。它们可以在化合物纯化中或在制备其它药学上课接受的盐中充当中间体或可用于本发明化合物的鉴别、表征或纯化。
术语“胺盐”是指用酸中和烷基伯胺、仲胺或叔胺得到的产物。所述酸包括本申请中所述的无机酸或有机酸。
当将本发明式中与手性碳的键描写直成线时,应当理解为,手性碳的(R)和(S)两种构型和由此产生的其对映体纯的化合物和混合物两者包括在该通式范围内。本文中消旋体或者对映体纯的化合物的图示法来自Maehr,J.Chem.Ed.1985,62:114-120。用楔形键和虚线键表示一个立体中心的绝对构型。
在本申请中,“药物组合物”是指本发明化合物与本领域通常接受的用于将生物活性化合物输送至哺乳动物(例如人)的介质的制剂。该介质包括药学上可接受的载体。药物组合物的目的是促进生物体的给药,利于活性成分的吸收进而发挥生物活性。
在本申请中,“药学上可接受的载体”包括但不限于任何被相关的政府管理部门许可为可接受供人类或家畜使用的佐剂、载体、赋形剂、助流剂、增甜剂、稀释剂、防腐剂、染料/着色剂、矫味剂、表面活性剂、润湿剂、分散剂、助悬剂、稳定剂、等渗剂、溶剂或乳化剂。
本发明的化合物可以在一个或多个构成该化合物的原子上包含非天然比例的原子同位素。例如,可用放射性同位素标记化合物,比如氘(2H),氚(3H),碘-125(125I)或C-14(14C)。本发明的化合物的所有同位素组成的变换,无论放射性与否,都包括在本发明的范围之内。
术语“辅料”是指可药用惰性成分。术语“赋形剂”的种类实例非限制性地包括粘合剂、崩解剂、润滑剂、助流剂、稳定剂、填充剂和稀释剂等。赋形剂能增强药物制剂的操作特性,即通过增加流动性和/或粘着性使制剂更适于直接压缩。
本文所用的术语“治疗”和其它类似的同义词包括以下含义:
(i)预防疾病或病症在哺乳动物中出现,特别是当这类哺乳动物易患有该疾病或病症,但尚未被诊断为已患有该疾病或病症时;
(ii)抑制疾病或病症,即遏制其发展;
(iii)缓解疾病或病症,即,使该疾病或病症的状态消退;或者
(iv)减轻该疾病或病症所造成的症状。
在符合本领域常识的基础上,上述各优选条件,可任意组合,即得本发明各较佳实例。
本发明所用试剂和原料均市售可得。
本发明的积极进步效果在于:
提供了一种如第一方面所述的微管蛋白-SRC双靶点抑制剂的方法及中间体,所述方法操作简单、收率高、纯度高,可用于医药工业化生产。
本发明人经过广泛而深入地研究,意外地开发了一种微管蛋白-SRC双靶点抑制剂,所述双靶点抑制剂具有如本发明第一方面所述的结构。其可以作为微管蛋白和Src激酶双靶点抑制剂,也可以作为单独的微管蛋白或Src激酶抑制剂使用。实验表明,本发明所述的抑制剂能明显抑制微管蛋白单体的聚合和抑制细胞增殖;对光化性角化病具有很好的治疗作用;符合皮肤局部给药的药代动力学性质;潜在全身毒性小,成药性好;具有很好的p-SRC抑制活性,能阻断SRC下游信号通路。
附图说明
图1为化合物对微管蛋白聚合抑制试验结果。
具体实施方式
以下结合具体实施例,进一步说明本发明。需理解,以下的描述仅为本发明的最优选实施方式,而不应当被认为是对于本发明保护范围的限制。在充分理解本发明的基础上,下列实施例中未注明具体条件的实验方法,通常按照常规条件,或按照制造厂商所建议的条件,本领域技术人员可以对本发明的技术方案作出非本质的改动,这样的改动应当被视为包括于本发明的保护范围之中的。
中间体A1的制备
室温下将N-苄基-2-(5-溴吡啶-2-基)乙酰胺(2.0g,6.55mmol),4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯酚(1.73g,7.86mmol)、氟化钾(1.52g,26.2mmol)和1,1′-二(二苯膦基)二茂铁二氯化钯(II)(480mg,0.66mmol)加入到反应瓶中,以氮气置换三次,然后加入溶剂二氧六环(20mL)和水(2mL),反应液在80℃下搅拌10h,TLC检测反应完成后冷却到室温,浓缩旋蒸掉溶剂得到粗品,过柱纯化N-苄基-2-(5-(4-羟基苯基)吡啶-2-基)乙酰胺(中间体A1)(1.65g,产率79%)。
LC-MS,M/Z(ESI):319.2[M+H]+
中间体A2的制备
第一步:3-氯-4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯酚的制备
室温下将化合物4-溴-3-氯苯酚(5.0g,24.10mmol),K2CO3(9.99g,72.3mmol),和联硼酸频那醇酯(12.24g,48.2mmol),1,1′-二(二苯膦基)二茂铁二氯化钯(II)(1.76g,2.41mmol)加入到二氧六环(80mL)中,氮气保护下85℃搅拌12h。待反应完全,加入水(100mL)稀释,用乙酸乙酯(50mL×3)萃取,分液,合并有机相,有机相用无水硫酸钠干燥,过滤,浓缩,残留物用柱层析纯化(石油醚:乙酸乙酯(V/V)=2:3)得化合物3-氯-4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯酚(2.6g,白色固体,产率42.4%)。
第二步:N-苄基-2-(5-(2-氯-4-羟基苯基)吡啶-2-基)乙酰胺的制备
将化合物3-氯-4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯酚(2.1g,8.25mmol),N-苄基-2-(5-溴吡啶-2-基)乙酰胺(2.77g,9.08mmol),碳酸钾(3.42g,24.75mmol)和1,1-双(二苯基膦)二茂铁二氯化钯(0.065g,0.089mmol)加入到二氧六环中(30mL)中,置换氮气,升温至85℃搅拌10h。加入水(100mL)稀释,用乙酸乙酯(30mL×3)萃取,分液,合并有机相。有机相用无水硫酸钠干燥,过滤,浓缩,残留物用层析柱分离纯化(石油醚:乙酸乙酯(V/V)=3∶2)得化合物N-苄基-2-(5-(2-氯-4-羟基苯基)吡啶-2-基)乙酰胺(中间体A2)(2.6g,白色固体,产率42.4%)。
实施例1化合物I-1的制备
合成路线如下所示
第一步:4-(4-溴苯氧基)-2-甲基丁-2-醇的制备
室温下将化合物4-溴-2-甲基丁-2-醇(0.5g,2.99mmol)和4-溴苯酚(0.59g,3.29mmol)加入到N,N-二甲基甲酰胺(10mL)中,然后加入碳酸铯(1.46g,4.49mmol),氮气保护下加热至120℃,搅拌16h。反应液冷却至室温,加入水(50mL)稀释,用乙酸乙酯(50mL×3)萃取,分液,合并有机相。有机相用无水硫酸钠干燥,过滤,浓缩,残留物用薄层硅胶板分离纯化(石油醚∶乙酸乙酯(V/V)=5∶1)得化合物4-(4-溴苯氧基)-2-甲基丁-2-醇(400mg,产率51.6%)。
第二步:2-甲基-4-(4-(4,4,5,5-四甲基-1,3,2-二氧杂硼烷-2-基)苯氧基)丁-2-醇的制备
室温下将化合物4-(4-溴苯氧基)-2-甲基丁-2-醇(0.3g,1.2mmol)和联硼酸频那醇酯(0.88g,3.47mmol)加入到1,4-二氧六环(5mL)中,然后加入醋酸钾(0.34g,3.47mmol),氮气保护下加入1,1′-二(二苯膦基)二茂铁二氯化钯(II)(42mg,0.058mmol),加热至100℃,搅拌6h。反应液冷却至室温,加入水(50mL)稀释,用乙酸乙酯(50mL×3)萃取,分液,合并有机相。有机相用无水硫酸钠干燥,过滤,浓缩,残留物用薄层硅胶板分离纯化(石油醚∶乙酸乙酯(V/V)=5∶1)得化合物2-甲基-4-(4-(4,4,5,5-四甲基-1,3,2-二氧杂硼烷-2-基)苯氧基)丁-2-醇(200mg,产率56.4%)。
第三步:N-苄基-2-(5-(4-(3-羟基-3-甲基丁氧基)苯基)吡啶-2-基)乙酰胺的制备
室温下将化合物2-甲基-4-(4-(4,4,5,5-四甲基-1,3,2-二氧杂硼烷-2-基)苯氧基)丁-2-醇(151mg,0.49mmol)和N-苄基-2-(5-溴吡啶-2-基)乙酰胺(100mg,0.33mmol)加入到乙二醇二甲醚(5mL)中,然后加入碳酸钠溶液(2mol/L,0.49ml),氮气保护下加入四(三苯基膦)钯(20mg,0.016mmol),加热到90℃搅拌10h。反应液冷却至室温,加入水(50mL)稀释,用乙酸乙酯(20mL×3)萃取,分液,合并有机相,有机相用无水硫酸钠干燥,过滤,浓缩,残留物经制备液相色谱纯化得N-苄基-2-(5-(4-(3-羟基-3-甲基丁氧基)苯基)吡啶-2-基)乙酰胺(I-1)(12.3mg,产率9.3%)。
1H NMR(400MHz,CDCl3)δ8.70(d,1H),7.82(dd,1H),7.70-7.60(m,2H),7.55-7.44(m,3H),7.35-7.28(m,3H),7.24(d,1H),7.04-6.99(m,2H),4.49(d,2H),4.26-4.19(m,2H),3.82(s,2H),2.13(s,1H),2.03(t,2H),1.33(d,6H)。
LC-MS,M/Z(ESI):405.3[M+H]+。
实施例2化合物I-2的制备
合成路线如下所示
第一步:1-(2-(4-溴苯氧基)乙基)-4-甲基哌啶-4-醇的制备
室温下将化合物1-溴-4-(2-溴乙氧基)苯(0.5g,1.78mmol),K2CO3(0.741g,5.36mmol)和4-甲基哌啶-4-醇(0.226g,1.96mmol)加入到乙腈(5mL)中,氮气保护下85℃搅拌12小时。待反应完全,加入水(10mL)稀释,用乙酸乙酯(5mL×3)萃取,分液,合并有机相,有机相用无水硫酸钠干燥,过滤,浓缩,残留物用薄层硅胶板分离纯化(石油醚∶乙酸乙酯(V/V)=2∶3)得化合物1-(2-(4-溴苯氧基)乙基)-4-甲基哌啶-4-醇(0.53g,白色固体,产率94%)。
第二步:4-甲基-1-(2-(4-(4,4,5,5-四甲基-1,3,2-二氧杂硼戊环-2-基)苯氧基)乙基)哌啶-4-醇的制备
将化合物1-(2-(4-溴苯氧基)乙基)-4-甲基哌啶-4-醇(0.28g,0.891mmol),联硼酸频那醇酯(0.339g,1.337mmol),醋酸钾(0.262g,2.67mmol)和1,1-双(二苯基膦)二茂铁二氯化钯(0.065g,0.089mmol)加入到二氧六环中(3.0mL)中,置换氮气,升温至85℃搅拌10小时。加入水(10mL)稀释,用乙酸乙酯(10mL×3)萃取,分液,合并有机相。有机相用无水硫酸钠干燥,过滤,浓缩,得粗品4-甲基-1-(2-(4-(4,4,5,5-四甲基-1,3,2-二氧杂硼戊环-2-基)苯氧基)乙基)哌啶-4-醇(0.18g,产率56%)。
第三步:N-苄基-2-(5-(4-(2-(4-羟基-4-甲基哌啶-1-基)乙氧基)苯基)吡啶-2-基)乙酰胺的制备
将4-甲基-1-(2-(4-(4,4,5,5-四甲基-1,3,2-二氧杂硼戊环-2-基)苯氧基)乙基)哌啶-4-醇(0.18g,0.498mmol),N-苄基-2-(5-溴吡啶-2-基)乙酰胺(0.304g,0.996mmol)和四三苯基膦钯(0.058g,0.05mmol),碳酸钠(0.158g,1.495mmol)加入到乙二醇二甲醚(3ml)和水(0.5ml)中升温至100℃搅拌12小时。加入水(5mL)稀释,用乙酸乙酯(5mL×3)萃取,分液,合并有机相。有机相用无水硫酸钠干燥,过滤,浓缩,残留物用薄层硅胶板分离纯化(石油醚:乙酸乙酯(V/V)=1:2),再用制备液相色谱纯化得N-苄基-2-(5-(4-(2-(4-羟基-4-甲基哌啶-1-基)乙氧基)苯基)吡啶-2-基)乙酰胺(I-2)(60mg,产率26.2%)。
LC-MS,M/Z(ESI):460.3[M+H]+。
1H NMR(400MHz,CDCl3)δ8.70(d,1H),7.81(dd,1H),7.64(s,1H),7.49(d,2H),7.31(dt,4H),7.24(d,2H),7.01(d,2H),4.49(d,2H),4.23(t,2H),3.82(s,2H),2.89(d,4H),2.66(s,2H),1.82(s,2H),1.65(d,2H),1.28(s,3H)。
实施例3化合物I-3的制备
合成路线如下所示:
室温下将N-苄基-2-(5-(4-羟基苯基)吡啶-2-基)乙酰胺(中间体A1)(0.1g,0.31mmol),和碳酸铯(0.61g,0.89mmol)加入到微波反应瓶中,再加入溶剂二甲亚砜(2mL),在80℃下搅拌10min,然后加入1-氯-2-甲基丙-2-醇(0.21g,0.89mmol),微波180℃下反应2h,TLC检测反应完成后冷却到室温,制备纯化得到N-苄基-2-(5-(4-(2-羟基-2-甲基丙氧基)苯基)吡啶-2-基)乙酰胺(I-3)(19mg,产率15%)。
1H NMR(400MHz,DMSO-d6)δ8.74(d,1H),8.64-8.59(m,1H),7.96(dd,1H),7.66-7.61(m,2H),7.39(d,1H),7.34-7.21(m,5H),7.05(d,2H),4.65(s,1H),4.30(d,2H),3.76(s,2H),3.71(s,2H),1.25-1.18(m,6H)。
LC-MS,M/Z(ESI):391.2[M+H]+
实施例4化合物I-4的制备
合成路线如下所示:
第一步:1-(2-溴乙基)环丙-1-醇的制备
室温下将3-溴丙酸乙酯(2.0g,12.0mmol)和钛酸四乙酯(3.4g,12mmol)加入无水四氢呋喃(20mL)中,冷却到0℃,缓慢滴加乙基溴化镁(19.2mL,2M in THF)。滴加完成室温搅拌12h。TLC监测反应完成后用水(20mL)淬灭反应,在加5%(v/v)硫酸(20mL)处理反应液,用乙酸乙酯(20mL*3)萃取混合物,用饱和碳酸氢钠水溶液(20mL)和饱和溴化钠水溶液(20mL)洗涤合并的萃取液,蒸发溶剂,残余物经硅胶色谱纯化(石油醚/乙酸乙酯=8∶1-4∶1为洗脱液),得到1-(2-溴乙基)环丙醇(1.1g,产率56%)。
第二步:N-苄基-2-(5-(4-(2-(1-羟基环丙基)乙氧基)苯基)吡啶-2-基)乙酰胺的制备
室温下将N-苄基-2-(5-(4-羟基苯基)吡啶-2-基)乙酰胺(0.2g,0.63mmol)和碳酸钾(0.26g,1.89mmol)加入到无水乙腈中(5mL),加热到80℃搅拌1h,然后加入1-(2-溴乙基)环丙-1-醇(0.11g,0.94mmol),继续加热在80℃下搅拌10h,TLC检测反应完成,反应液冷却到室温,浓缩旋蒸掉溶剂得到粗品,经制备高效液相色谱纯化得化合物N-苄基-2-(5-(4-(2-(1-羟基环丙基)乙氧基)苯基)吡啶-2-基)乙酰胺(I-4)(126mg,产率49%).
1H NMR(400MHz,DMSO-d6)δ8.74(d,1H),8.61(t,1H),7.96(dd,1H),7.64(dd,2H),7.39(d,1H),7.35-7.18(m,5H),7.04(d,2H),5.24(s,1H),4.29(t,2H),4.24-4.17(m,2H),3.71(s,2H),1.93(t,2H),0.58(dd,2H),0.46(dd,2H).
LC-MS,M/Z(ESI):403.2[M+H]+
实施例5-15
下列化合物的制备参考本发明其他化合物的合成方法:
/>
/>
实施例16化合物I-16的制备
合成路线如下所示:
室温下将N-苄基-2-(5-(2-氯-4-羟基苯基)吡啶-2-基)乙酰胺(0.4g,1.13mmol)和碳酸钾(0.47g,3.4mmol)加入到无水乙腈中(15mL),加热到85℃下搅拌1h,然后加入4-溴-2-甲基丁-2-醇(0.57g,3.40mmol),继续加热在85℃下搅拌10h,点板检测反应完成后冷却到室温,浓缩旋蒸掉溶剂得到粗品,用硅胶柱分离纯化得化合物N-苄基-2-(5-(2-氯-4-(3-羟基-3-甲基丁氧基)苯基)吡啶-2-基)乙酰胺(I-16)(0.34g,产率68%).
1H NMR(400MHz,DMSO-d6)δ8.66(t,1H),8.51(d,1H),7.79(dd,1H),7.40(dd,2H),7.35-7.20(m,4H),7.17(d,1H),7.03(dd,1H),4.43(s,1H),4.31(d,2H),4.16(t,2H),3.74(s,2H),1.85(t,2H),1.17(s,6H).
LC-MS,M/Z(ESI):439.2[M+H]+
本发明测试例中的对照化合物I(商品名Tirbanibulin)是一种双重作用的Src激酶和微管蛋白聚合抑制剂,已被FDA和欧盟获批用于面部或头皮光化性角化病的局部治疗。对照化合物I的制备参考专利WO 2008/002676 A2,对照化合物I结构如下:
测试例1:抑制微管蛋白单体聚合试验
采用Tubulin Polymerization Assay Kit(cytoskeleton,Cat.#BK011P)开展化合物抑制微管蛋白单体聚合试验。
试验前先将试剂盒配套的96孔板(Corning Costar,Cat.#3686)放置于酶标仪(MD,SpectraMaxM5)中加热至37℃,维持10min,取出96孔板,加入5μL的12.5μM的化合物溶液或空白溶液,再将96孔板放入酶标仪37℃孵育1min,使化合物溶液升温至37℃,取出96孔板于每孔迅速加入按照供应商说明书配置的反应混合物50μL,1min内完成加样并避免产生气泡,然后立即将96孔板放入酶标仪,震荡5s,使用Kinetic mode在激发光360nm、发射光420nm条件下,37℃连续检测30min-60min,每30s检测一次,以检测时间为X轴,荧光信号值为Y轴得到微管蛋白单体聚合曲线。如图1所示,聚合曲线的Vmax值越大和最大荧光信号值越高代表化合物抑制效率越低。
表1
化合物对微管蛋白聚合抑制试验结果如图1和表1所示,结果表明,本发明化合物对应的聚合曲线的最大荧光信号值明显更小,说明其能明显抑制微管蛋白单体的聚合,与对照化合物I相比,抑制活性更优。
测试例2:化合物抑制细胞增殖试验
采用人皮肤鳞状细胞癌细胞A-431(ATCC,CRL-1555)、人胚胎肾上皮细胞293T(中国典型培养物保藏中心,GDC0187)增殖试验检测小分子化合物对细胞增殖抑制作用。
A-431细胞、293T细胞培养于含10%胎牛血清的DMEM培养基中,于37℃,5%CO2培养箱中生长。将对数期细胞按照1000个细胞/孔,每孔100μL接种于96孔细胞培养板,置于37℃,5%CO2培养箱培养过夜。第二天每孔再加入100μL梯度稀释的2×待测化合物溶液,DMSO作为阳性对照,另设置10μM十字孢碱(阿拉丁,S102392)作为阴性对照组,加完化合物的培养板继续于37℃,5%CO2培养箱中孵育4天。孵育完成后使用 luciferase assaysystem(Promega,G9243)并按照供应商提供的说明书在Envision 2104Multilabel Reader上测定荧光信号值。通过以下公式计算抑制率,然后以抑制剂的浓度Log值为X轴,抑制率为Y轴绘制曲线,用Graphpad 8.0计算得出IC50。
Inhibition%=(阳性对照组信号-测试孔信号)/(阳性对照组信号-阴性对照组信号)*100
表2测试化合物对不同细胞增殖活性抑制结果
/>
表3测试化合物对不同细胞增殖活性抑制结果
化合物对细胞增殖抑制试验结果如表2和3所示,结果表明,本发明化合物能明显抑制细胞增殖。
测试例3:药代动力学试验
小鼠药代动力学试验,使用3只雄性ICR小鼠,20-25g,禁食过夜,尾静脉注射给药(1mg/kg或5mg/kg)。在给药前和给药后15、30min以及1、2、4、8、24h采血。血液样品于6800g,2-8℃离心6min,收集血浆,于-80℃保存。取各时间点血浆,加入3-5倍量含内标的乙腈溶液混合,涡旋混合1分钟,13000转/min下于4℃离心10min,取上清液加入3倍量水混合,取适量混合液进行LC-MS/MS分析。主要药代动力学参数用WinNonlin 7.0软件非房室模型分析。
表4小鼠药代动力学试验结果
表5小鼠药代动力学试验结果
小鼠药代动力学试验结果如表4和5所示,结果表明,本发明化合物体内代谢快,潜在毒性小,成药性良好。
尽管上面已经示出和描述了本发明的实施例,可以理解的是,上述实施例是示例性的,不能理解为对本发明的限制,本领域的普通技术人员在本发明的范围内可以对上述实施例进行变化、修改、替换和变型。
Claims (23)
1.式I所示化合物或其药学上可接受的盐,具有结构:
其中,W选自:-O-、-S-、-NH-、-N(C1-C6烷基)-;
Q为
L1为C1-C6亚烷基;
L2、L3各自独立地为不存在或为C1-C6亚烷基;
且L2和L3不同时不存在;
环A为3-6元环烷基或4-8元杂环基;
环B不存在或选自:3-8元环烷基、4-10元杂环基、6-10元芳基、5-10元杂芳基;
所述L1、L2、L3任选地被一个或多个RL取代;当RL为多个时,所述RL相同或不同;
RL、Rb、R1、R2各自独立地选自:卤素、羟基、氨基、氰基、C1-C6烷基、C2-C6烯基、C2-C6炔基、-O-C1-C6烷基、-COO-C1-C6烷基、-CO-C1-C6烷基、-C(O)NR11R12;
其中,R11、R12各自独立地为氢、C1-C6烷基;
所述RL、Rb、R1、R2任选地被一个或多个选自下列的取代基取代:卤素、羟基、氨基、氰基、C1-C6烷基,当取代基为多个时,所述取代基相同或不同;
m为0、1、2或3;当Rb为多个时,所述Rb相同或不同;
n为0、1、2或3;当R1为多个时,所述R1相同或不同;
p为0、1、2或3;当R2为多个时,所述R2相同或不同。
2.如权利要求1所述的化合物或其药学上可接受的盐,其特征在于,选自:
3.如权利要求1所述的化合物或其药学上可接受的盐,其特征在于,W选自:-O-、-S-、-NH-;较佳地,W为-O-。
4.如权利要求2所述的化合物或其药学上可接受的盐,其特征在于,为/>
5.如权利要求1或2所述的化合物或其药学上可接受的盐,其特征在于,环A为3-6元环烷基或4-6元杂环基;
L1、L2、L3任选地被一个或多个RL取代;当RL为多个时,所述RL相同或不同;
所述RL选自:卤素、羟基、氨基、氰基、C1-C6烷基、-O-C1-C6烷基;
所述RL任选地被一个或多个选自下列的取代基取代:卤素、羟基、氨基、氰基、C1-C6烷基;当取代基为多个时,所述取代基相同或不同;
较佳地,所述RL选自:C1-C6烷基或C1-C6卤代烷基;
较佳地,环A为3-6元环烷基;
较佳地,所述卤素为F。
6.如权利要求1或2所述的化合物或其药学上可接受的盐,其特征在于,环B选自:3-8元环烷基、4-10元杂环基;
较佳地,环B选自:3-6元环烷基、4-6元杂环基;
较佳地,所述环B为单环、并环、桥环、螺环;
较佳地,所述3-6元环烷基、4-6元杂环基为单环;
较佳地,所述环B具有1、2或3选自N、O、S、P的杂原子;
较佳地,所述环B具有S杂原子,所述环B具有结构
7.如权利要求1或2所述的化合物或其药学上可接受的盐,其特征在于,m为0、1或2;
Rb选自:卤素、羟基、氨基、氰基、C1-C3烷基、C2-C4烯基、C2-C4炔基、-O-C1-C3烷基、-COO-C1-C3烷基、-CO-C1-C3烷基、-C(O)NR11R12;
其中,R11、R12各自独立地为氢、甲基、乙基、丙基;
所述Rb任选地被一个或多个选自下列的取代基取代:卤素、羟基、氨基、氰基、C1-C3烷基,当取代基为多个时,所述取代基相同或不同;
或Rb选自:卤素、羟基、氨基、氰基、C1-C6烷基、-O-C1-C6烷基;
所述Rb任选地被一个或多个选自下列的取代基取代:卤素、C1-C6烷基;当取代基为多个时,所述取代基相同或不同;
较佳地,Rb选自:C1-C6烷基;所述Rb任选地被一个或多个卤素取代;当卤素为多个时,所述卤素相同或不同;
较佳地,Rb选自:甲基、乙基、丙基、异丙基;所述Rb任选地被一个或多个卤素取代;当卤素为多个时,所述卤素相同或不同;
较佳地,所述卤素为F。
8.如权利要求1或2所述的化合物或其药学上可接受的盐,其特征在于,
具有结构
9.如权利要求1所述的化合物或其药学上可接受的盐,其特征在于,n为0或1;
R1选自:卤素、氰基、C1-C6烷基;
较佳地,R1选自:氟、氰基、甲基。
10.如权利要求1所述的化合物或其药学上可接受的盐,其特征在于,其满足以下条件中的一个或多个:
(1)W选自-O-;
(2)Q为L1为C1-C6亚烷基;环B不存在或选自:3-8元环烷基、4-10元杂环基;Rb、R1各自独立地选自:卤素、C1-C6烷基;m为0或1;
(3)n为0或1;
(4)p为0。
11.如权利要求1所述的化合物或其药学上可接受的盐,其特征在于,W选自-O-;
Q为
L1为C1-C6亚烷基;
环B不存在或选自:3-8元环烷基、4-10元杂环基;
Rb、R1各自独立地选自:卤素、C1-C6烷基;
m为0或1;
n为0或1;
p为0。
12.如权利要求1所述的化合物或其药学上可接受的盐,其特征在于,其满足以下条件中的一个或多个:
(1)所述的环B里,所述的3-8元环烷基为3-6元环烷基;
(2)所述的环B里,所述的3-8元环烷基为单环、并环、桥环或螺环;
(3)所述的环B里,所述的3-8元环烷基为饱和环;
(4)所述的环B里,所述的4-10元杂环基为4-6元杂环基;
(5)所述的环B里,所述的4-10元杂环基为单环、并环、桥环或螺环;
(6)所述的环B里,所述的4-10元杂环基为饱和环;
(7)所述的环B里,所述的4-10元杂环基中的杂原子为N或O;
(8)所述的环B里,所述的4-10元杂环基通过N原子与L1连接;
(9)所述的Rb里,所述的卤素为氟或氯;
(10)所述的Rb里,所述的C1-C6烷基为甲基或乙基;
(11)所述的R1里,所述的卤素为氟或氯;
(12)所述的R1里,所述的C1-C6烷基为甲基或乙基;
(13)选自:/>
13.如权利要求1所述的化合物或其药学上可接受的盐,其特征在于,其满足以下条件中的一个或两个:
(1)所述的环B里,所述的3-8元环烷基为环丙基、环丁基、环戊基、环己基;
(2)所述的环B里,所述的4-10元杂环基为
14.如权利要求1所述的化合物或其药学上可接受的盐,其特征在于,包括:
15.一种药物组合物,包括如权利要求1-14中任一所述的化合物或其药学上可接受的盐。
16.一种药物组合物,包括如权利要求1-14中任一所述的化合物或其药学上可接受的盐,和
药学上可接受的载体和/或其他活性药物。
17.如权利要求1-14中任一所述的化合物或其药学上可接受的盐的用途,或权利要求15所述的药物组合物的用途,或权利要求16所述的药物组合物的用途,所述用途包括:
1)抑制微管蛋白聚合和/或Src激酶、
2)制备微管蛋白聚合和/或Src激酶抑制剂、
3)制备预防和/或治疗与微管蛋白聚合和/或Src激酶相关的疾病的药物、药物组合物或制剂;
较佳地,所述与微管蛋白聚合和/或Src激酶相关的疾病包括肿瘤、皮肤疾病;
较佳地,所述药物为外用制剂;
较佳地,所述药物为经皮给药的药物。
18.如权利要求1-14中任一所述的化合物或其药学上可接受的盐在制备治疗肿瘤和/或皮肤疾病的药物中的用途;或如权利要求15所述的药物组合物在制备治疗肿瘤和/或皮肤疾病的药物中的用途;或如权利要求16所述的药物组合物在制备治疗肿瘤和/或皮肤疾病的药物中的用途;
较佳地,所述药物为外用制剂;
较佳地,所述药物为经皮给药的药物。
19.如权利要求18所述的用途,其特征在于,所述肿瘤包括:实体瘤、肉瘤、血液系统癌症;
较佳地包括:乳腺癌、卵巢癌、前列腺癌、子宫颈癌、睾丸癌、结肠癌、结肠直肠癌、肝癌、非小细胞肺癌、鳞状细胞癌、小细胞肺癌、胃癌、胃肠道间质瘤、胰腺癌、膀胱癌、生殖细胞瘤、肥大细胞瘤、肥大细胞增多症、胶质母细胞瘤、神经母细胞瘤、星形细胞瘤、黑色素瘤、B细胞淋巴瘤、T细胞淋巴瘤、缓慢进展淋巴瘤、霍奇金淋巴瘤、非霍奇金淋巴瘤、急性髓细胞性白血病、急性淋巴细胞性白血病、慢性髓细胞性白血病、慢性淋巴细胞性白血病、骨髓瘤和/或骨髓增生异常综合症。
20.如权利要求18所述的用途,其特征在于,所述皮肤疾病包括:光化性角化病、银屑病、异位性皮炎、牛皮癣、白癜风、玫瑰疹和/或系统性红斑狼疮。
21.一种抑制Src激酶的方法,包括步骤:给需要的对象使用如权利要求1-14中任一所述的化合物或其药学上可接受的盐,或如权利要求15所述的药物组合物,或如权利要求16所述的药物组合物。
22.一种抑制微管蛋白的方法,包括步骤:给需要的对象使用如权利要求1-14中任一所述的化合物或其药学上可接受的盐,或如权利要求15所述的药物组合物,或如权利要求16所述的药物组合物。
23.一种化合物,其特征在于,所述化合物为如下任一化合物
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210045140 | 2022-01-14 | ||
CN2022100451405 | 2022-01-14 | ||
CN202210399396 | 2022-04-15 | ||
CN2022103993966 | 2022-04-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116444425A true CN116444425A (zh) | 2023-07-18 |
Family
ID=87126245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310074547.5A Pending CN116444425A (zh) | 2022-01-14 | 2023-01-13 | 微管蛋白-src双靶点抑制剂 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116444425A (zh) |
WO (1) | WO2023134753A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024041628A1 (zh) * | 2022-08-25 | 2024-02-29 | 武汉人福创新药物研发中心有限公司 | 二芳基类化合物及其制备方法和用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1836169T3 (pl) * | 2004-12-28 | 2012-07-31 | Kinex Pharmaceuticals Llc | Kompozycje i sposoby leczenia zaburzeń związanych z proliferacją komórek |
CN101595084B (zh) * | 2006-06-29 | 2013-01-02 | 金克斯医药品有限公司 | 用于调整激酶级联的二芳基组合物和方法 |
WO2011129936A2 (en) * | 2010-04-16 | 2011-10-20 | Kinex Pharmaceuticals, Llc | Compositions and methods for the prevention and treatment of cancer |
US9926273B2 (en) * | 2012-08-30 | 2018-03-27 | Athenex, Inc. | Composition and methods for modulating a kinase cascade |
CN114516832B (zh) * | 2020-11-20 | 2023-11-28 | 成都贝诺科成生物科技有限公司 | 一种微管蛋白抑制剂及其制备方法与应用 |
CN115477608B (zh) * | 2021-06-16 | 2023-12-12 | 成都贝诺科成生物科技有限公司 | 一种微管蛋白抑制剂及其制备方法与应用 |
-
2023
- 2023-01-13 CN CN202310074547.5A patent/CN116444425A/zh active Pending
- 2023-01-13 WO PCT/CN2023/072144 patent/WO2023134753A1/zh unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024041628A1 (zh) * | 2022-08-25 | 2024-02-29 | 武汉人福创新药物研发中心有限公司 | 二芳基类化合物及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
WO2023134753A1 (zh) | 2023-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113164409B (zh) | 具有雌激素受体α降解活性的化合物及其用途 | |
EP4144732A1 (en) | Benzothiazolyl biaryl compound, and preparation method and use | |
BR112018008877B1 (pt) | Compostos inibidores de ret, composição farmacêutica e usos dos referidos compostos | |
US9518022B2 (en) | Anti-HIV compounds | |
WO2022100624A1 (zh) | 氧取代氨基碳酸酯噻吩类化合物及其用途 | |
WO2018149231A1 (zh) | 7H-吡咯并[2,3-d]嘧啶衍生物及抗肿瘤的应用 | |
EP3786167A1 (en) | Diaryl macrocyclic compound and pharmaceutical composition, and use thereof | |
CN116194440A (zh) | 喹唑啉酮hsd17b13抑制剂及其用途 | |
CN116323578A (zh) | 噻吩hsd17b13抑制剂及其用途 | |
CN116444425A (zh) | 微管蛋白-src双靶点抑制剂 | |
TW202028209A (zh) | 作為RET激酶抑制劑的取代的咪唑[1,2-a]吡啶和[1,2,4]三唑[1,5-a]吡啶化合物 | |
US20190084988A1 (en) | Wdr5 inhibitors and modulators | |
AU2014294225B2 (en) | Novel triazine derivative | |
KR20230146640A (ko) | 융합된 폴리사이클릭 치환된 5-카복실산 티에노피리미딘 디온 화합물 및 이의 용도 | |
CN116444426A (zh) | 微管蛋白-Src双靶点抑制剂和用途 | |
CN116444427A (zh) | 用于微管蛋白-src双靶点抑制剂的二芳基类化合物 | |
CN111447931B (zh) | 抗癌/抗纤维化化合物 | |
EP2192122B1 (en) | Dithiolopyrrolone compounds, the preparation and the use thereof | |
WO2022171088A1 (zh) | 吡唑并[3,4-d]嘧啶-3-酮衍生物 | |
CN115448881A (zh) | 杂芳基类化合物、其制备方法及其在医药上的应用 | |
TW202227444A (zh) | 四環類化合物及其醫藥用途 | |
CN106966986A (zh) | N‑苄基硝基杂环烯酮缩胺类衍生物及合成方法和抗肿瘤应用 | |
CN108640965B (zh) | 2-取代-18β-甘草次酸衍生物及其应用 | |
WO2021143927A1 (zh) | 作为bcr-abl抑制剂的化合物 | |
CN112724134B (zh) | 氮杂吲唑联吡啶衍生物髓细胞增殖抑制剂及其制备方法与在制药中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication |